Related Experiment Videos
The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate
Insights
Gemfibrozil effectively reduced high cholesterol and triglyceride levels in hyperlipidemia patients. This lipid-lowering drug also increased HDL cholesterol, offering a potential therapeutic option.
Area of Science:
- Cardiology
- Pharmacology
- Metabolic Disorders
Background:
- Hyperlipidemia is a significant risk factor for cardiovascular disease.
- Current treatments aim to manage lipid profiles, but novel therapeutic strategies are continuously explored.
- Gemfibrozil is a fibrate drug known for its lipid-modifying properties.
Purpose of the Study:
- To evaluate the efficacy of gemfibrozil in managing hyperlipidemia.
- To compare gemfibrozil's effects against placebo and other lipid-lowering agents.
- To assess the impact of gemfibrozil on key lipid parameters, including cholesterol, triglycerides, VLDL, and HDL.
Main Methods:
- A single-blind study involving 33 hyperlipidemic patients.
- Gemfibrozil (1600 mg daily) was administered and compared with placebo and other drugs (primarily clofibrate) over nine months.
- Adverse events, particularly gastrointestinal symptoms, were monitored.
Main Results:
- Gemfibrozil significantly reduced plasma cholesterol and triglyceride levels compared to placebo.
- The drug demonstrated a significant decrease in very low-density lipoprotein (VLDL) triglycerides.
- Gemfibrozil led to a significant increase in high-density lipoprotein (HDL) cholesterol levels.
- The inverse relationship between VLDL triglyceride and HDL cholesterol observed with placebo was abolished by gemfibrozil.
Conclusions:
- Gemfibrozil is an effective agent for lowering plasma cholesterol and triglycerides in patients with hyperlipidemia.
- The drug positively modulates HDL cholesterol levels, suggesting a potential benefit in cardiovascular risk reduction.
- While generally effective, gastrointestinal side effects necessitate careful patient monitoring.
Abstract:
In a single-blind study the lipid-lowering drug gemfibrozil was compared at fixed dosage of 1600 mg daily with placebo and other drugs (mainly clofibrate) over a nine month period in 33 patients with hyperlipidaemia. Two patients were withdrawn from the study because of gastrointestinal symptoms attributable to gemfibrozil. The drug significantly lowered plasma cholesterol and triglycerides compared to the placebo. The drug also significantly lowered plasma cholesterol and triglycerides compared to the placebo. The drug also significantly lowered very low density lipoprotein (VLDL) triglycerides and raised high density lipoprotein (HDL) cholesterol levels but a previously significant inverse relationship between VLDL triglyceride and HDL cholesterol on placebo disappeared with gemfibrozil treatment.